大疱性类天疱疮诊断时抗BP180自身抗体水平与1年死亡率相关
诊断时高抗BP180自身抗体水平、痴呆、住院时长和年龄与1年死亡率显著相关,抗体浓度≥61 U/mL可识别早期死亡高风险亚组。
要点
- 诊断时抗BP180抗体水平高与大疱性类天疱疮患者1年死亡率独立相关。
- 抗体浓度≥61 U/mL提示早期死亡风险显著升高。
- 痴呆、住院时长和年龄也是1年死亡率的独立相关因素。
核心结论
- 大疱性类天疱疮诊断时血清抗BP180自身抗体浓度有助于识别诊断后第一年内死亡风险高的患者,cut-off值为61 U/mL。
主要发现
- 1年死亡率为25.0%,较一般人群死亡风险增加2.4倍。
- 诊断时高抗BP180自身抗体水平(CI95 1.30-2.89;P=0.001)、痴呆(CI95 1.13-6.72;P=0.03)、住院时长(CI95 1.16-2.41;P=0.01)和年龄(CI95 1.23-4.19;P=0.009)与1年死亡率显著相关。
- 抗BP180自身抗体浓度≥61 U/mL的患者亚组较一般人群早期死亡风险更高(CI95 1.81-3.81;P<0.0001)。
关键数值与推荐
- 抗BP180自身抗体浓度≥61 U/mL被确定为提示早期死亡风险增加的cut-off值。
临床怎么用
- 对大疱性类天疱疮患者,诊断时可检测血清抗BP180自身抗体水平,若≥61 U/mL则提示需关注早期死亡风险并加强随访管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bullous pemphigoid (BP) is the most frequent autoimmune blistering disease mainly affecting elderly patients. Among several published risk factors, a recent post hoc analysis linked anti-BP180 autoantibodies (AABs) to fatal outcomes in BP. To date, this finding has not been confirmed independently. OBJECTIVE: To investigate the potential of anti-BP180-AAB levels as a marker of prognosis and to identify a cut-off level indicative of an increased risk for early death. Secondly, to characterize parameters associated with mortality. METHODS: Retrospective, single-centre study of BP patients diagnosed between 2001 and 2012. Analyses included epidemiological and patient- and disease-specific characteristics as well as immunological parameters at diagnosis and during follow-up. Standardized mortality ratios as well as uni- and multivariate regression analyses were calculated. RESULTS: One hundred patients (56 women, 44 men) with a median age of 81 years (interquartile range 74-86) were followed up for a median of 775 days (interquartile range 162-1617). One-year mortality rates were 25.0% implying a 2.4-fold increased risk of death compared with the general population. High anti-BP180 autoantibody levels at diagnosis (CI95 1.30-2.89; P = 0.001), dementia (CI95 1.13-6.72; P =0.03), length of hospitalization (CI95 1.16-2.41; P = 0.01) and age (CI95 1.23-4.19; P = 0.009) correlated significantly with 1-year mortality. BP180-AAB concentrations of ≥61 U/mL characterized a subgroup of patients with a particular higher risk for early death compared with the general population (CI95 1.81-3.81; P < 0.0001). CONCLUSION: In bullous pemphigoid, serum concentrations of BP180 autoantibodies at diagnosis could help to identify patients at risk for death within the first year after diagnosis (cut-off value 61 U/mL).
引用
- Monshi B, Gulz L, Piringer B, et al. Anti-BP180 autoantibody levels at diagnosis correlate with 1-year mortality rates in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol. 2020. PMID: 32170780. doi:10.1111/jdv.16363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。